Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity

Discrepancies between HIV-1 RNA results assayed by different FDA-approved platforms have been reported. Plasma samples collected from 332 randomly selected clinical trial participants during the second year of antiretroviral treatment were assayed with three FDA-approved platforms: UltraSensitive Ro...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Microbiol
Main Authors: Lalama, Christina M., Jennings, Cheryl, Johnson, Victoria A., Coombs, Robert W., McKinnon, John E., Bremer, James W., Cobb, Bryan R., Cloherty, Gavin A., Mellors, John W., Ribaudo, Heather J.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2015
Assuntos:
Virology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4508432/
https://ncbi.nlm.nih.gov/pubmed/26063861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JCM.00801-15
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares